It has been suggested that the effects of rosiglitazone and other TZDs on mitochondrial biogenesis and insulin sensitivity could be mediated in part by PGC-1α, since amelioration of insulin resistance and induction of mitochondrial gene expression by TZDs is paralleled by an increase in PGC-1α levels [2], [10], [17]. Here, INS is linked to Insulin resistance.